| Autor: |
Alroughani, Raed, VAN WIJMEERSCH, Bart, Al Khaboori, Jabber, Alsharoqi, Isa Ahmed, Ahmed, Samar F., Hassan, Ali, Inshasi, Jihad, Krieger, Derk W., Shakra, Mustafa, Shatila, Ahmed Osman, Szolics, Miklos, Khallaf, Mohamed, Ezzat, Aly |
| Přispěvatelé: |
Alroughani, Raed/0000-0001-5436-5804 |
| Jazyk: |
angličtina |
| Rok vydání: |
2020 |
| Předmět: |
|
| Popis: |
Over the past decade, the development of high-efficacy disease-modifying therapies (DMTs) has been responsible for more effective management of relapsing-remitting multiple sclerosis (RRMS). However, the gaps in optimal care for this complex disease remain. Alemtuzumab (Lemtrada (R)) is a highly efficacious DMT that shows better patient outcomes and therapeutic benefits, but its use is under-recognized in the Gulf region. Experts in the care of multiple sclerosis shared their opinions based on study data and daily clinical experience in identifying the appropriate patient profile suitable for alemtuzumab's therapeutic benefits. Age, disease activity and severity, disability status, physician experience, and economic condition are some of the key indicators for alemtuzumab use. The authors disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: The meeting of the expert group was organized and funded by Sanofi Genzyme. A medical writer (Haniya Dawn Panizales, Ogilvy Health and Wellness) provided medical writing assistance. All authors edited the manuscript for intellectual content and approved the final version. The final responsibility for the content lies with the authors. Alroughani, R (corresponding author), Al Amiri Hosp, Dept Med, Div Neurol, Kuwait, Kuwait. alroughani@gmail.com |
| Databáze: |
OpenAIRE |
| Externí odkaz: |
|
